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Abstract
Background:
Careful management of lipid abnormalities in patients with coronary heart disease (CHD) or an acute coronary syndrome (ACS) can reduce the risk of recurrent
cardiovascular events. The extent of hyperlipidemia in these very high-risk patients in the United Arab Emirates (UAE), along with the treatment strategies employed, is
not clear.
Methods:
The Dyslipidemia International Study II was a multinational observational analysis carried out from 2012 to 2014. Patients were enrolled if they had either stable CHD
or an ACS. Patient characteristics, lipid levels, and use of lipid-lowering therapy (LLT) were recorded at enrollment. For the ACS patients, the LLT used during the 4
months' follow-up period was documented, as were any cardiovascular events.
Results:
A total of 416 patients were recruited from two centers in the UAE, 216 with stable CHD and 200 hospitalized with an ACS. Comorbidities and cardiovascular risk
factors were extremely common. A low-density lipoprotein cholesterol level of <70 mg/dl, recommended for patients at very high cardiovascular risk, was attained by
39.3% of the LLT-treated CHD patients and 33.3% of the LLT-treated ACS patients at enrollment. The mean atorvastatin-equivalent daily statin dose was 29 ± 15 mg for
the CHD patients, with 13.7% additionally using ezetimibe. For the ACS patients, the daily dosage was 23 ± 13 mg at admission, rising to 39 ± 12 mg by the end of the
4-month follow-up. The use of nonstatin agents was extremely low in this group.
Conclusions:
Despite LLT being widely used, hyperlipidemia was found to be prevalent in ACS and CHD patients in the UAE. Treatment strategies need to be significantly improved
to reduce the rate of cardiovascular events in these very high-risk patients.
Keywords: Cholesterol, coronary artery disease, dyslipidemia, lipids, statins
INTRODUCTION
Cardiovascular disease is a growing problem throughout the world. In 2010, 29% of deaths in the United Arab Emirates (UAE) were caused by this condition.[1]
Individuals with coronary heart disease (CHD) are at very high risk for suffering recurrent cardiovascular adverse events, both fatal and nonfatal. In order to improve the
outcome for these patients, management of associated risk factors such as diabetes mellitus, hypertension, and dyslipidemia is of paramount importance. In the UAE,
these comorbidities are highly prevalent in the general population and found to an alarming extent in younger people.[2,3,4] This had led to the control of cardiovascular
risk factors being the number one health-care priority in the UAE.[1,5]
The treatment of hyperlipidemia with the use of lipid-lowering therapy (LLT) such as statins has been shown to be highly effective for improving cardiovascular health.
[6,7,8] Reducing levels of low-density lipoprotein cholesterol (LDL-C) in particular are the major focus of strategies to prevent and slow the progression of CHD.
[9,10,11] Indeed, it has been demonstrated that lowering LDL-C levels by around 39 mg/dl (1 mmol/l) could reduce the 5-year occurrence of major vascular events by
approximately a fifth.[6] The most recent guidelines from the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) advocate an
LDL-C level of <70 mg/dl (1.8 mmol/l) for patients at very high cardiovascular risk, such as those with established CHD and other comorbidities.[10] However, despite
treatment with LLT, the majority of patients have failed to attain this goal. In the first Dyslipidemia International Study (DYSIS), of the 30 countries involved, the UAE
and Kuwait combined were found to have the highest proportion of very high-risk statin-treated patients with an LDL-C level below 70 mg/dl (44.9%).[12] In
comparison, the Middle East and Africa region as a whole had a value of 26.6%, with the lowest target achievement being for Spain at only 10.1%.[12,13] In the
Centralized Pan-Middle East Survey on the under-treatment of hypercholesterolemia (CEPHEUS), the Arabian Gulf countries, which included the UAE, it was found
that 31.9% of very high-risk patients had an LDL-C level of <70 mg/dl,[14] while only 24.8% of the Levant cohort were at goal.[15]
Such poor target attainment clearly warrants further investigation. DYSIS II was established to quantify the prevalence, characteristics, and treatment of hyperlipidemia
in individuals with CHD or an acute coronary syndrome (ACS). Here, we present the data collected from these very high-risk patients in the UAE.
METHODS
Patients
Patients were recruited from two centers in the UAE from November 2013 to November 2014. Individuals were enrolled if they were diagnosed with either stable CHD
or were hospitalized due to an ACS, were over 18 years of age, and had a full lipid profile available. ACS was defined as an ST-segment elevation myocardial infarction
(STEMI)/left bundle branch block myocardial infarction (LBBB MI), non-ST-STEMI (NSTEMI), or unstable angina (UA). For patients with CHD, the last blood test
before enrollment was evaluated to provide the lipid profile; for patients with an ACS, a blood test carried out within 24 h of admission to hospital was used. Patients
were excluded if they were participating in a clinical trial at the same time as the study. ACS patients that died during hospitalization were also excluded. If any patients
were receiving LLT, the duration of treatment had to be ≥3 months before enrollment. For the patients with stable CHD, data were collected at the baseline physician
visit. For patients hospitalized owing to an ACS, data were collected on admission to hospital and at 4 months (±15 days) postadmission.
All patients that were enrolled provided written informed consent. The study received ethical approval from the relevant committees at each participating center and was
carried out in accordance with the Declaration of Helsinki and its amendments.
Documentation
Data were first recorded on a standardized case report form (CRF) and were then entered into a central online database maintained at the Institut für
Herzinfarktforschung, Ludwigshafen, Germany.
Patient demographics, cardiovascular risk factors, comorbidities, and current LLT were documented at enrollment. These included age, gender, and body mass index
(BMI); current smoking or a sedentary lifestyle; presence of type 2 diabetes mellitus or hypertension; a history of CHD, chronic renal failure (CRF), chronic kidney
disease, or peripheral artery disease; a prior MI or stroke (ischemic or hemorrhagic); and any family history of CHD. Obesity was defined as BMI >30 kg/m . Diabetes
was defined as current treatment for diabetes, a previous diagnosis of diabetes, or a fasting plasma glucose level of ≥126 mg/dl; hypertension was defined as current
treatment, a previous diagnosis, or having blood pressure >140/90 mmHg. A sedentary lifestyle was defined as <20–30 min of walking on <3–4 days/week.
Cardiovascular medications used at admission were also documented, including ACE inhibitors, antiplatelet agents, beta-blockers, calcium channel blockers, and
diuretics. A full lipid profile was recorded, which included serum levels of total cholesterol (TC), LDL-C, high-density lipoprotein cholesterol (HDL-C), non-HDL-C,
and triglycerides.
For ACS patients, preadmission cardiovascular risk status was determined according to the ESC/EAS guidelines, with targets for LDL-C for very high risk, high risk,
moderate risk, and low-risk patients defined as <70 mg/dl (1.8 mmol/l), <100 mg/dl (2.6 mmol/l), <115 mg/dl (3.0 mmol/l), and <130 mg/dl (3.4 mmol/l), respectively.
[10] Very high and high-risk patients are determined according to the presence of comorbidity, while risk factors or markers such as obesity and high C-reactive protein
are additionally taken into account for determining moderate and low cardiovascular risk. LDL-C goal attainment by risk status was based on the lipid values
determined at admission, which reflected lipid levels from the preadmission period. The median distance to the LDL-C target was calculated for patients who had not
attained this level at the time of the lipid profile.
Patients were divided into subgroups based on whether they were being treated with LLT at the time of the latest lipid test (CHD patients) or admission to hospital (ACS
patients). The following classes of LLT were assessed: statin monotherapy, nonstatin monotherapy, statin plus ezetimibe, and statin plus other nonstatin therapy (other
nonstatins included nicotinic acid, fibrates, omega-3 fatty acids, and other less common agents). The statins assessed were atorvastatin, fluvastatin, lovastatin,
pitavastatin, pravastatin, rosuvastatin, and simvastatin. Atorvastatin-equivalent daily dosages were based on clinical trial data regarding the LDL-C-lowering efficacy of
various statins.[16]
For ACS patients, at 4 months (±15 days) postadmission, any lipid profiles collected since hospital discharge were obtained, and the medications that the subjects were
receiving at this time were documented. Any cardiovascular-related adverse events that occurred during the follow-up period were recorded. These were not mutually
exclusive and included rehospitalization, MI, stroke, percutaneous coronary intervention, and coronary artery bypass grafting.
Statistics
Throughout the text, the term “LLT-treated” refers to the treatment status at the time of the lipid test, either that before the enrolment visit (CHD patients) or that at
admission for the initial ACS. Data are presented as means with standard deviations, medians with interquartile ranges, or absolute values with percentages. LDL-C
target attainment was assessed first by risk classification and then, in the subgroup of patients with LDL-C data at both admission and follow-up. The Chi-squared test or




A total of 416 patients were recruited, 216 with stable CHD and 200 with an ACS. The mean age of the CHD individuals was 65.9 ± 11.2 years and 65.3% (141/216)
were male [Table 1]. The majority of subjects were Arabic (92.1%; 199/216), with Indians making up 5.6% (12/216). Obesity (BMI >30 kg/m ) was highly prevalent at
46.8% (101/216), while only 8.8% (19/216) of patients were noted to be current smokers. Comorbidities were common, in particular, type 2 diabetes mellitus (84.3%;
182/216) and hypertension (89.4%; 193/216). Only five of the 216 patients were not being treated with LLT at the time of enrollment.
The patients with an ACS had a mean age of 55.6 ± 10.8 years and 87.5% (175/200) were male [Table 2]. In terms of ethnicity, 49.5% (99/200) were Arab and 39.0%
(78/200) were Indian. Obesity was documented for 23.5% (47/200), while 27.0% (54/200) were current smokers and 85% (170/200) reported a sedentary lifestyle. Of
the 200 patients enrolled, 129 (64.5%) were being treated with LLT before their ACS. This group of subjects was slightly older than the no LLT group (57.3 vs. 52.5
years; P = 0.0028) and contained a lower proportion of smokers (21.7% vs. 36.6%; P = 0.023). All other characteristics were similar for the LLT and no LLT patients.
Comorbidities were more common for the LLT group in comparison to the no LLT, in particular, type 2 diabetes (55.0% vs. 23.9%; P = 0.00002) and hypertension
(72.1% vs. 39.4%; P < 0.00001). A smaller proportion of the LLT group was diagnosed with a STEMI or an MI/LBBB in comparison to the no LLT group (39.5% vs.
57.7%; P = 0.013). The rate of NSTEMI was similar between groups, while UA was more often diagnosed for the LLT group (20.2% vs. 8.5%; P = 0.031).
Lipid profile at the time of latest lipid test
The mean LDL-C level of the LLT-treated patients with stable CHD was slightly above the recommended target at 81.7 ± 32.7 mg/dl [Table 3]. The median HDL-C
level was 41.0 (32.0, 49.0) mg/dl, the median non-HDL-C level was 100.0 (82.0, 127.0) mg/dl, the median TC level was 147.0 (121.0, 169.0) mg/dl, and the median
triglyceride level was 122.0 (87.0, 168.0) mg/dl. A total of 39.3% (83/211) of the LLT-treated CHD patients had an LDL-C level of <70 mg/dl, with the median distance
to this value being 23.0 (8.5, 44.0) mg/dl. Multivariate logistic regression identified type 2 diabetes mellitus as being predictive of achieving an LDL-C level below 70
mg/dl (odds ratio [OR]: 3.01; 95% confidence interval [CI]: 1.03–8.73; P 0.043), while patients aged 70 years or older were less likely to reach this target (OR: 0.34;
95% CI: 0.17–0.70; P = 0.0032) [Table 4].
For the LLT-treated ACS patients, the mean LDL-C level was 94.0 ± 38.6 mg/dl, LDLC-C < 70 mg/dl based on ESC/EAS guidelines [Table 3].[10] The median HDL-C
level was 34.0 (29.0, 40.0) mg/dl, the median non-HDL-C level was 116.0 (91.0, 148.0) mg/dl, the median TC level was 155.0 (125.0, 186.0) mg/dl, and the median
triglyceride level was 143.0 (94.0, 203.0) mg/dl. An LDL-C level of <70 mg/dl was attained by 33.3% (43/129) of the LLT-treated ACS patients, with the median
distance to this target being 38.0 (22.0, 60.0) mg/dl. When subdivided according to preadmission risk status, 33.3% of the 93 very high-risk LLT-treated ACS patients
had reached their LDL-C target of <70 mg/dl, 44.4% of the 9 high-risk patients had achieved their target of <100 mg/dl, 66.7% of the 15 moderate-risk patients had
achieved their target of <115 mg/dl, and 90.9% of the 11 low-risk patients had achieved their target of <130 mg/dl [Figure 1]. Out of the variables investigated in the
multivariable analysis, stable angina was found to be predictive of achieving an LDL-C level of <70 mg/dl [OR: 5.00; 95% CI: 1.30–19.21; P 0.020; Table 4].
During the 4-month follow-up, new lipid profiles were available for only 29 of the ACS patients, 19 of those being treated with LLT at baseline and 10 of those that
were not. For this group of patients, target attainment rose from 32.1% (9/28) at baseline to 44.8% (13/29) at 4 months.
Lipid-lowering therapy at the time of latest lipid test
At enrollment, 97.7% (211/216) of the patients with stable CHD were being treated with LLT [Table 5]. The majority of patients were receiving a statin as part of their
treatment, with atorvastatin being the most commonly prescribed (71.3%; 149/209). When normalized to atorvastatin potency,[16] the mean daily statin dosage was 29 ±
15 mg. About 13.7% (29/211) of the CHD patients were being treated with ezetimibe in addition to a statin, with 7.6% (16/211) taking a statin plus other nonstatin
medication.
Of the 198 ACS patients with available information, 64.6% were receiving LLT before admission, with all of these taking a statin as part of their treatment regimen.
Atorvastatin was the most commonly prescribed (60.9%; 78/128). Only a single patient was being treated with a statin plus ezetimibe, while two (1.6%) were being
treated with a statin plus other nonstatin. The mean atorvastatin-equivalent daily statin dosage was 23 ± 13 mg.
At the 4-month follow-up point, it was found that 97.0% (161/166) of the ACS patients were being treated with LLT, with all but one of these taking a statin as part of
their therapy [Table 5].[16] Atorvastatin was used in the majority of cases (83.1%; 133/160), with rosuvastatin being the next most common (15.0%; 24/160). The use of
nonstatin agents was rare, with one patient (0.6%) taking a statin plus ezetimibe and six (3.7%) taking a statin plus other nonstatin.
Events during follow-up for acute coronary syndrome patients
No patients died during the 4-month follow-up period, but nine (4.9%) required rehospitalization. Of these, a single rehospitalization was necessary in seven cases, with
three or more needed in the other two. An ACS was stated as the reason for the first readmission in only two cases.
DISCUSSION
Hyperlipidemia was found to be widespread in patients with stable CHD and those hospitalized for an ACS in the UAE. While LDL-C target achievement appeared to
be higher than reported for other countries, it was still poor. LLT was extensively used, especially in patients with established CHD; however, statin dosages were not
maximized. There is clearly wide scope for improvements in how LLT is prescribed in these very high-risk patients.
Patients
The patients with stable CHD had extreme levels of cardiovascular risk factors and comorbidities. Obesity was highly prevalent, being reported for almost half of the
subjects. In a recent survey, obesity was found for 19.6% of the general population of the UAE,[4] while a cardiovascular screening program involving native Emiratis
demonstrated a rate of 35.4%.[2] Such a high frequency of this risk factor in the general population would understandably translate to a higher prevalence in our CHD
patients, which were predominantly Arabic. This worrying level of obesity has been linked to the rapid changes in lifestyle that have accompanied the oil-driven
economic growth of the UAE.[1] The high-calorie diet and sedentary lifestyle now adopted by much of the population also helps to explain the alarming prevalence of
diabetes mellitus (84.7%) that was found in the patients with stable CHD in our study. Again, the rate of diabetes reported for the general population provides some
rationalization for this finding. In a survey carried out in the year 2000, 20.2% of included subjects had a diagnosis of diabetes, with the rate being 24.5% when
considering only native UAE citizens.[3] More recent studies have reported values of just over 30%, indicating a growing problem.[4,17] In the first DYSIS study,
66.9% of the Middle Eastern statin-treated patients had diabetes,[18] while in CEPHEUS-Arabian Gulf, the value was 63.5%.[14] In terms of hypertension, almost 90%
of our CHD patients displayed this, a value that is higher than the 78.1% found in DYSIS-Middle East and 66.6% in CEPHEUS-Arabian Gulf.[14,18] These high rates
of risk factors demonstrate the extremely poor cardiovascular health of these predominantly Arab CHD patients.
The patients enrolled owing to hospitalization for an ACS were younger than those with stable CHD, and the racial makeup of the group differed significantly. While
most of the CHD patients were Arabic, almost 40% of those with an ACS were of Indian origin. There were also large differences in terms of the prevalence of
cardiovascular risk factors. The rate of obesity (23.5%) was closer to that described for the general population of the UAE (19.6%).[4] This may be explained by the
differences between South Asian expatriates and native UAE citizens within this prior screening study, with obesity rates of 14.1% and 46.6%, respectively, being
documented.[4] Similar findings were observed for the prevalence of diabetes mellitus in our study. While a significant proportion of the ACS patients had this
condition, it was approximately 40% smaller than that of the CHD patients. Again, Yusufali et al. described a higher rate of diabetes in native UAE citizens in
comparison to South Asian expatriates.[4] A sedentary lifestyle was common for the ACS patients, a problem linked to the urbanization of the UAE and increasing
dependence on modern technology.[1] In combination, these studies show alarming levels of cardiovascular risk factors in the Arab population of the UAE.
Lipid profile and low-density lipoprotein cholesterol target attainment
Despite the poor cardiovascular health of the patients with stable CHD, the mean LDL-C level for the LLT group was only approximately 10 mg/dl above the
recommended target of <70 mg/dl, with 39.3% having attained this goal. While such target achievement is poor, it is higher than that reported for the very high-risk
patients in other studies. In the most recent EUROASPIRE report, only 19.5% of CHD patients had an LDL-C level at goal, despite widespread use of LLT,[19] while in
the Middle East, CEPHEUS-Levant gave a value of 24.8%.[15] In the first DYSIS study, the UAE and Kuwait combined had the highest target attainment rate for very
high-risk patients of all 30 countries included in the analysis (44.9%).[12] In comparison, 26.6% of the Middle East and Africa patients reached the target, 19.1% of
those from Europe/Canada/Israel, and 23.9% of those from China.[13] The consistently superior LDL-C levels found in the UAE compared to other countries are
surprising given the aforementioned rates of cardiovascular risk factors and comorbidities and require further investigation. However, the extremely high prevalence of
type 2 diabetes mellitus is likely to play a significant role, with the presence of this condition being found to be predictive of target attainment. The lipid profile
characteristic of type 2 diabetes includes an atherogenic combination of high levels of triglycerides and low levels of HDL-C, while elevated LDL-C is less common.
[20,21] Therefore, although LDL-C target attainment appears superior in the UAE, alternative lipid abnormalities should not be overlooked.
Lipid abnormalities were more abundant for the ACS patients, with high LDL-C combined with low HDL-C levels. Accordingly, the proportion of LLT-treated patients
that had attained the <70 mg/dl goal was lower at 33.3%. A further point to note is that very few of the ACS patients had a repeat lipid test performed during the 4-
month follow-up. This suggests poor monitoring of such high-risk patients. Improved follow-up may reduce the occurrence of recurrent adverse cardiovascular events.
Lipid-lowering therapy
Almost all of the patients with stable CHD were being treated with LLT at the time of their latest lipid test; however, the high proportion of patients that were not at the
LDL-C target suggests that the therapy was not being administered effectively. For the ACS patients, a lower proportion was being treated with LLT before admission,
but this increased significantly after hospitalization. The atorvastatin-equivalent dosage was low before the ACS admission, and although it increased up to follow-up, it
remained below 40 mg/day. Guidelines recommend initiating intensive statin therapy after an ACS,[10] the benefits of which have been shown in numerous trials.
Nicholls et al. demonstrated significant coronary plaque regression with intensive statin therapy in comparison to a standard.[22] In the Pravastatin or Atorvastatin
Evaluation and Infection Therapy–Thrombolysis in MI 22 study, patients were found to have a lower likelihood of death or a major cardiovascular event after suffering
an ACS if treated with intensive rather than standard therapy.[23,24] In the IDEAL study, no difference in the rates of major coronary events was seen, but intensive
therapy led to improvements in the achievement of other cardiovascular endpoints such as nonfatal MI.[25] In these and other studies, an atorvastatin dosage of 80 mg
was generally used as the intensive arm,[26,27] a value that is much higher than the average of 39 mg found in the present analysis. This highlights the significant
under-use of LLT in these very high-risk patients. The inadequate use of statins may have been influenced by the known dose-dependent side-effects causing reluctance
on the part of the physician to prescribe high doses.[28,29]
The addition of a nonstatin agent such as ezetimibe or a fibrate is an alternative means by which LLT can be intensified, in particular for patients who cannot tolerate
high doses of statins. In the Vytorin Efficacy International Trial, it was shown that, in patients that had suffered an ACS, LDL-C levels were lowered more effectively
when ezetimibe was added to simvastatin treatment (93.8–53.7 mg/dl during the trial) than when simvastatin was used alone (93.8–69.5 mg/dl during the trial).[30] A
2% lower rate of primary endpoint achievement (cardiovascular death, nonfatal MI, UA requiring hospitalization, coronary revascularization, or nonfatal stroke) was
also demonstrated for the patients receiving combination therapy. Increased plaque regression in patients with CHD has also been demonstrated for ezetimibe used with
rosuvastatin in comparison to rosuvastatin used alone.[31,32] In the present study, the use of nonstatin LLT was quite common for the patients with CHD, with over
20% using combination therapy. For the ACS patients, however, use of such treatment was limited to just a few cases both at admission and at follow-up. This perhaps
indicates a missed opportunity for intensification of LLT after an ACS.
The small number of events and rehospitalizations that occurred during the follow-up period prevents us from making comparisons between treatment patterns and
cardiovascular outcome. Therefore, the true effect of this under-treatment cannot be demonstrated.
Limitations
One limitation of this analysis is that the relatively small size of the population resulted in very few patients with stable CHD that were not being treated with LLT at
enrollment, making the statistical value of any comparisons low. The small number of patients with a new lipid profile available at follow-up was a further drawback,
again preventing useful comparisons being made. However, this demonstrates poor monitoring of ACS patients after hospital discharge, which is a finding in itself. A
further limitation was that only two centers were included. The short follow-up time resulted in few adverse events being recorded, preventing the identification of any
associations between lipid levels, treatment strategies, and cardiovascular outcome.
CONCLUSIONS
Although the rate of attainment of the recommended LDL-C target of <70 mg/dl was higher in the UAE than those reported for other countries, it was still poor. LLT
was widely used in both patients with stable CHD and those with an ACS; however, treatment was rarely maximized. As shown in this and other studies, in native
Emiratis, in particular, rates of comorbidities are alarmingly high in the UAE. In order to reduce morbidity and mortality in this country, more effective treatment
strategies for hyperlipidemia and associated cardiovascular risk factors need to be rapidly employed.
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Figures and Tables
Table 1
Patient characteristics - stable coronary heart disease cohort
Open in a separate window
*Includes ischemic and hemorrhagic stroke, >3 months prior to enrollment. LLT: Lipid-lowering therapy, BMI: Body mass index, SBP: Systolic blood pressure, DBP: Diastolic blood
pressure, CV: Cardiovascular, CHD: Coronary heart disease, CKD: Chronic kidney disease, PAD: Peripheral artery disease, ACS: Acute coronary syndrome, SD: Standard deviation,
CABG: Coronary artery bypass grafting, IQR: Interquartile range, PCI: Percutaneous coronary intervention. Data presented as median (IQR), mean±SD, or percentage (n/N). P values
not calculated due to small sample size
Table 2
Patient characteristics - acute coronary syndrome cohort
Open in a separate window
*Includes ischemic and hemorrhagic stroke. LLT: Lipid-lowering therapy, BMI: Body mass index, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, CV: Cardiovascular,
CHD: Coronary heart disease, CKD: Chronic kidney disease, PAD: Peripheral artery disease, ACS: Acute coronary syndrome, STEMI: ST-segment elevation myocardial infarction,
LBBB MI: Myocardial infarction with left bundle branch block, NSTEMI: Non-ST-elevation myocardial infarction, SD: Standard deviation, IQR: Interquartile range. Data presented as
median (IQR), mean±SD, or percentage (n/N). P values calculated using Chi-squared test or Mann–Whitney–Wilcoxon test
Table 3
Lipid profile (latest blood test*)
Stable CHD ACS
Total (n=216) LLT (n=211) No LL (n=5) Total (n=200) LLT (n=129) No LLT (n=71) P (LLT vs. no
LLT)
LDL-C (mg/dl), mean±SD 82.5±32.9 81.7±32.7 118.2±19.4 105.0±44.9 94.0±38.6 124.9±49.0 <0.0001




























LDL-C <70 mg/dl 38.4 (83/216) 39.3 (83/211) 0.0 (0/5) 23.6 (47/199) 33.3 (43/129) 5.7 (4/70) <0.0001
Distance to LDL-C <70 mg/dl 24.0 (9.0-45.0) 23.0 (8.5-44.0) 44.0 (38.0-62.0) 42.0 (24.0-71.5) 38.0 (22.0-60.0) 54.5 (32.0-78.0) <0.01
*CHD patients: Last recorded lipid profile prior to physician visit, ACS patients: Within 24 h of admission for ACS event, ESC/EAS guidelines. LDL-C: Low-density lipoprotein
cholesterol, HDL-C: High-density lipoprotein cholesterol, TC: Total cholesterol, LLT: Lipid-lowering therapy, CHD: Coronary heart disease, ACS: Acute coronary syndrome, SD:
Standard deviation, IQR: Interquartile range, ESC: European Society of Cardiology, EAS: European Atherosclerosis Society. Data presented as median (IQR) or percentage (n/N). P
values for LLT versus no LLT in the ACS cohort calculated using Chi-squared test or Mann–Whitney–Wilcoxon test. P values not calculated for LLT versus no LLT in the stable CHD
cohort due to small sample size
Table 4
Multiple logistic regression model for low-density lipoprotein cholesterol< 70 mg/dl for patients receiving lipid-lowering therapy at baseline
Variable CHD patients ACS patients
OR (95% CI) P OR (95% CI) P
Age ≥70 years 0.34 (0.17-0.70) 0.0032 0.67 (0.12-3.74) 0.64
Female gender 0.54 (0.27-1.11) 0.09 0.82 (0.23-2.92) 0.76
BMI >30 kg/m 0.84 (0.43-1.63) 0.61 1.34 (0.54-3.61) 0.50
Current smoking* 0.60 (0.18-2.00) 0.40 - -
Sedentary lifestyle 0.67 (0.29-1.56) 0.35 4.63 (0.72-29.78) 0.11
Stable angina 0.44 (0.22-0.89) 0.02 5.00 (1.30-19.21) 0.020
Type 2 diabetes 3.01 (1.03-8.73) 0.043 1.78 (0.73-4.34) 0.20
Hypertension 0.53 (0.19-1.52) 0.24 0.43 (0.16-1.13) 0.087
Statin dose (calculated as atorvastatin equivalent, mg/day) 1.01 (0.99-1.03) 0.28 1.01 (0.98-1.05) 0.56
CKD 1.71 (0.85-3.45) 0.13 3.12 (0.57-17.07) 0.19
History of congestive heart failure 0.86 (0.41-1.83) 0.70 1.21 (0.25-5.95) 0.82
*ACS analysis excluded due to low number of patients. BMI: Body mass index, The model includes all displayed variables, which were selected based on clinical relevance. CHD:
Coronary heart disease, ACS: Acute coronary syndrome, CI: Confidence interval, OR: Odds ratio, CKD: Chronic kidney disease
Figure 1
Target low-density lipoprotein cholesterol attainment in ACS patients (% at goal) by risk level prior to ACS Original figure. Risk level determined according the European Society of
Cardiology/European Atherosclerosis Society guidelines. Total population: Very high risk: n = 129 (LLT 93, no LLT 36); high risk: n = 12 (LLT 9, no LLT 3); moderate risk: n = 34 (LLT 15, no
LLT 19); low risk: n = 23 (LLT 11, no LLT 12)
Table 5
Lipid-lowering therapy at time of latest lipid test
Stable CHD* (n=216) ACS
Hospital admission (n=198) 4-month follow-up (n=166)
Treated with LLT (%) 97.7 (211/216) 64.6 (128/198) 97.0 (161/166)
Statin therapy (%) 96.8 (209/216) 64.6 (128/198) 96.4 (160/166)
 Atorvastatin 71.3 (149/209) 60.9 (78/128) 83.1 (133/160)
 Fluvastatin 0.0 (0/209) 0.0 (0/128) 0.0 (0/160)
 Lovastatin 0.0 (0/209) 0.0 (0/160) 0.0 (0/160)
 Pitavastatin 0.0 (0/209) 0.0 (0/128) 0.0 (0/160)
 Pravastatin 1.9 (4/209) 0.0 (0/128) 0.6 (1/160)
 Rosuvastatin 22.5 (47/209) 21.1 (27/128) 15.0 (24/160)
 Simvastatin 3.8 (8/209) 3.9 (5/128) 0.6 (1/160)
 Unknown 0.5 (1/209) 14.1 (18/128) 0.6 (1/160)
Statin daily dose - atorvastatin equivalents (mg/day) 29±15 (n=208) 23±13 (n=110) 39±12 (n=159)
Statin daily dose - simvastatin equivalents (mg/day) 58±31 (n=208) 47±25 (n=110) 79±25 (n=159)
Stain monotherapy (%) 77.7 (164/211) 97.7 (125/128) 95.0 (153/161)
Nonstatin monotherapy (%) 0.9 (2/211) 0.0 (0/128) 0.6 (1/161)
Statin + ezetimibe (%) 13.7 (29/211) 0.8 (1/128) 0.6 (1/161)
Statin + other nonstatin (%) 7.6 (16/211) 1.6 (2/128) 3.7 (6/161)
*LLT at time of latest lipid test, Dose equivalents calculated according to reference.[16] Data presented as mean±SD, or percentage (n/N). P values calculated using Chi-squared test or
Mann–Whitney–Wilcoxon test. SD: Standard deviation, LLT: Lipid-lowering therapy, CHD: Coronary heart disease, ACS: Acute coronary syndrome
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Total (n=216) LLT (n=211) No LLT (n=5)
Age (years) 65.9±11.2 65.7±11.1 74.2±15.8
Male (%) 65.3 (141/216) 64.5 (136/211) 100.0 (5/5)
Race/ethnicity
 Arabic 92.1 (199/216) 91.9 (194/211) 100.0 (5/5)
 Indian 5.6 (12/216) 5.7 (12/211) 0.0 (0/5)
 Black 0.9 (2/216) 0.9 (2/211) 0.0 (0/5)
 Caucasian 0.5 (1/216) 0.5 (1/211) 0.0 (0/5)
 Filipino 0.5 (1/216) 0.5 (1/211) 0.0 (0/5)
 Unknown 0.5 (1/216) 0.5 (1/211) 0.0 (0/5)
BMI (kg/m ) 29.6 (25.7-33.7) 29.6 (25.7-33.8) 28.3 (26.0-30.9)
BMI >30 kg/m  (%) 46.8 (101/216) 46.9 (99/211) 40.0 (2/5)
SBP (mmHg) 130 (117-145) 130 (116-145) 124 (122-140)
DBP (mmHg) 68 (60-75) 68 (60-75) 74 (62-76)
CV risk factors (%)
 Current smoker 8.8 (19/216) 8.5 (18/211) 20.0 (1/5)
 Sedentary lifestyle 83.9 (178/212) 84.1 (175/208) 75.0 (3/4)
 Family history of CHD 25.2 (35/139) 25.9 (35/135) 0.0 (0/4)
Comorbidities (%)
 Type 2 diabetes mellitus 84.3 (182/216) 84.8 (179/211) 60.0 (3/5)
 Hypertension 89.4 (193/216) 89.6 (189/211) 80.0 (4/5)
Total (n=200) LLT (n=129) No LLT (n=71) P (LLT vs. no LLT)
Age (years) 55.6±10.8 57.3±9.8 52.5±12.0 0.0028
Male (%) 87.5 (175/200) 85.3 (110/129) 91.5 (65/71) 0.20
Race/ethnicity
 Arabic 49.5 (99/200) 49.6 (64/129) 49.3 (35/71) 0.97
 Indian 39.0 (78/200) 40.3 (52/129) 36.6 (26/71) 0.61
 Black 0.5 (1/200) 0.8 (1/129) 0.0 (0/71) 0.46
 Caucasian 1.5 (3/200) 0.8 (1/129) 2.8 (2/71) 0.26
 Filipino 3.0 (6/200) 4.7 (6/129) 0.0 (0/71) 0.07
 Other Asian 6.5 (13/200) 3.9 (5/129) 11.3 (8/71) <0.05
BMI (kg/m ) 27.2 (24.4-29.8) 27.5 (24.3-30.1) 27.0 (24.5-29.0) 0.35
BMI >30 kg/m  (%) 23.5 (47/200) 27.1 (35/129) 16.9 (12/71) 0.10
SBP (mmHg) 123 (110-141) 120 (110-140) 124 (114-141) 0.25
DBP (mmHg) 73 (63-82) 73 (62-81) 71 (65-84) 0.50
CV risk factors (%)
 Current cigarette smoker 27.0 (54/200) 21.7 (28/129) 36.6 (26/71) 0.023
 Sedentary lifestyle 85.0 (170/200) 86.8 (112/129) 81.7 (58/71) 0.33
 Family history of CHD 22.3 (43/193) 28.7 (35/122) 11.3 (8/71) <0.01
Comorbidities (%)
 Type 2 diabetes mellitus 44.0 (88/200) 55.0 (71/129) 23.9 (17/71) 0.00002
 Hypertension 60.5 (121/200) 72.1 (93/129) 39.4 (28/71) <0.00001
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